Ribo Life Science Co., Ltd, a pioneer in the development of small interfering RNA (siRNA) therapies, has successfully debuted on the Main Board of the Hong Kong Stock Exchange. This achievement represents an important step forward for the capitalization of China’s biopharmaceutical sector in the siRNA space and brings renewed momentum to the industry.
Through its global initial public offering, Ribo issued 31,610,400 shares at a price of HKD 57.97 per share, generating gross proceeds exceeding HKD 1.8 billion. Investor demand was exceptionally strong, with the Hong Kong public offering oversubscribed by more than 100 times and the international placement receiving 16.7 times subscription. These results highlight robust global investor confidence in both the siRNA therapeutic landscape and Ribo’s technological strength.
The funds raised will provide substantial financial backing for the Company’s core operations and future growth. The offering also secured participation from 12 cornerstone investors, including Arc Avenue, Ivy Rock, Springs Capital, China Asset Management, Dacheng International, Dacheng Fund, and Taikang Life Insurance, underscoring institutional confidence in Ribo’s long-term development strategy.
Dr. Zicai Liang, Founder, Chairman, and Chief Executive Officer of Ribo, stated that the Company’s listing in Hong Kong marks a defining moment in its evolution. He expressed appreciation to global investors for their continued support and emphasized that Ribo will utilize international capital markets to speed up global clinical development and commercialization of its siRNA therapies, enhance its technological platforms, deliver innovative treatments to patients worldwide, and generate long-term value for shareholders.
The net proceeds from the IPO will be primarily allocated to four strategic areas: advancing global multicenter clinical trials for key products; funding preclinical and clinical pipeline development; upgrading siRNA delivery systems and related technology platforms; and strengthening working capital and general corporate operations.
Ribo has established a fully integrated research and development platform supported by proprietary intellectual property. Its proprietary liver-targeting RiboGalSTAR delivery technology has enabled multiple drug candidates to progress into Phase II clinical studies. The Company operates R&D centers in Suzhou, Beijing, and Gothenburg, Sweden, forming a global research network that supports the full drug development process, from discovery through international clinical trials.
The successful listing was jointly sponsored by China International Capital Corporation and Citigroup, whose expertise and support contributed to Ribo’s smooth entry into the public capital markets.
Through its global initial public offering, Ribo issued 31,610,400 shares at a price of HKD 57.97 per share, generating gross proceeds exceeding HKD 1.8 billion. Investor demand was exceptionally strong, with the Hong Kong public offering oversubscribed by more than 100 times and the international placement receiving 16.7 times subscription. These results highlight robust global investor confidence in both the siRNA therapeutic landscape and Ribo’s technological strength.
The funds raised will provide substantial financial backing for the Company’s core operations and future growth. The offering also secured participation from 12 cornerstone investors, including Arc Avenue, Ivy Rock, Springs Capital, China Asset Management, Dacheng International, Dacheng Fund, and Taikang Life Insurance, underscoring institutional confidence in Ribo’s long-term development strategy.
Dr. Zicai Liang, Founder, Chairman, and Chief Executive Officer of Ribo, stated that the Company’s listing in Hong Kong marks a defining moment in its evolution. He expressed appreciation to global investors for their continued support and emphasized that Ribo will utilize international capital markets to speed up global clinical development and commercialization of its siRNA therapies, enhance its technological platforms, deliver innovative treatments to patients worldwide, and generate long-term value for shareholders.
The net proceeds from the IPO will be primarily allocated to four strategic areas: advancing global multicenter clinical trials for key products; funding preclinical and clinical pipeline development; upgrading siRNA delivery systems and related technology platforms; and strengthening working capital and general corporate operations.
Ribo has established a fully integrated research and development platform supported by proprietary intellectual property. Its proprietary liver-targeting RiboGalSTAR delivery technology has enabled multiple drug candidates to progress into Phase II clinical studies. The Company operates R&D centers in Suzhou, Beijing, and Gothenburg, Sweden, forming a global research network that supports the full drug development process, from discovery through international clinical trials.
The successful listing was jointly sponsored by China International Capital Corporation and Citigroup, whose expertise and support contributed to Ribo’s smooth entry into the public capital markets.